1,902 results on '"*LEFT atrial appendage closure"'
Search Results
2. Registry on Luma Vision's VERAFEYE System (ENLIgHT) (ENLIgHT)
- Published
- 2024
3. Feasibility Study on the VERAFEYE System (LUMINIzE)
- Published
- 2024
4. Intracardiac Versus Transesophageal Echocardiographic Guidance for Left Atrial Appendage Occlusion (ICETEE)
- Published
- 2024
5. The Evaluation of Thrombogenicity in Patients Undergoing WATCHMAN Left Atrial Appendage Closure Trial
- Author
-
Boston Scientific Corporation
- Published
- 2024
6. Preprocedural cardiac computed tomography versus transesophageal echocardiography for planning left atrial appendage occlusion procedures.
- Author
-
Soh, Bing Wei Thaddeus, Gracias, Carlos Sebastian, Sim, Wee Han, Killip, Michael, Waters, Max, Millar, Kevin P., O'Brien, Julie M., Kiernan, Thomas J., and Arnous, Samer
- Abstract
The heterogeneous anatomy of the left atrial appendage (LAA) necessitates preprocedural imaging essential for planning of percutaneous LAA occlusion (LAAO) procedures. While transoesophageal echocardiography (TOE) remains the gold standard, cardiac computed tomography (CT) is becoming increasingly popular. To address the lack of consensus on the optimal imaging modality, we compared the outcomes of preprocedural TOE versus CT for LAAO procedure planning. A retrospective single-center cohort study of all LAAO procedures was performed to compare the outcomes of patients receiving preprocedural TOE versus those receiving CT. The primary outcome was procedural success and rate of major adverse events. The secondary outcomes were total procedure time, rate of device size change, and maximum landing zone diameter. A total of 64 patients was included. Of these, 25 (39.1%) underwent TOE and 39 (60.9%) underwent CT. There was no significant difference in the procedural success rate (96.0% vs. 100%, P = 0.39) or major adverse event rate (4.0% vs. 5.1%, P > 0.99) between TOE and CT patients. Compared with TOE, CT was associated with significantly shorter median procedure time (103 min vs. 124 min, P = 0.02) and a lower rate of device size change (7.7% vs. 28.0%, P = 0.04). Compared to CT, TOE was associated with a significantly smaller mean maximum landing zone diameter (20.8 mm vs. 25.8 mm, P < 0.01) and a higher rate of device upsizing (24.0% vs. 2.6%, P = 0.01). No significant difference in detected residual leak rates was found between TOE and CT (50.0% vs. 52.2%, P > 0.99). Planning of LAAO procedures with CT is associated with a shorter total procedure time and a lower rate of device size change and is less likely to underestimate the maximum landing zone diameter. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
7. Left atrial appendage closure for stroke prevention in atrial fibrillation: current status and perspectives.
- Author
-
Landmesser, Ulf, Skurk, Carsten, Tzikas, Apostolos, Falk, Volkmar, Reddy, Vivek Y, and Windecker, Stephan
- Subjects
LEFT atrial appendage closure ,MEDICAL care ,ATRIAL fibrillation ,ANTICOAGULANTS ,STROKE - Abstract
Atrial fibrillation (AF) is associated with an increased risk of stroke and systemic embolism, and the left atrial appendage (LAA) has been identified as a principal source of thromboembolism in these patients. While oral anticoagulation is the current standard of care, LAA closure (LAAC) emerges as an alternative or complementary treatment approach to reduce the risk of stroke or systemic embolism in patients with AF. Moderate-sized randomized clinical studies have provided data for the efficacy and safety of catheter-based LAAC, largely compared with vitamin K antagonists. LAA device iterations, advances in pre- and peri-procedural imaging, and implantation techniques continue to increase the efficacy and safety of LAAC. More data about efficacy and safety of LAAC have been collected, and several randomized clinical trials are currently underway to compare LAAC with best medical care (including non-vitamin K antagonist oral anticoagulants) in different clinical settings. Surgical LAAC in patients with AF undergoing cardiac surgery reduced the risk of stroke on background of anticoagulation therapy in the LAAOS III study. In this review, we describe the rapidly evolving field of LAAC and discuss recent clinical data, ongoing studies, open questions, and current limitations of LAAC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. Safety and effectiveness of left atrial appendage closure in atrial fibrillation patients with different types of heart failure.
- Author
-
Liu, Liping, Yan, Wen, Xu, Xiang, Wan, Chen, Liu, Feng, Yao, Qing, Song, Ling, Wang, Binbin, Song, Zhiyuan, and Li, Huakang
- Subjects
LEFT atrial appendage closure ,ATRIAL fibrillation ,VENTRICULAR ejection fraction ,TREATMENT effectiveness ,HEART failure - Abstract
Background: Both atrial fibrillation (AF) and heart failure (HF) are common cardiovascular diseases. If the two exist together, the risk of stroke, hospitalization for HF and all-cause death is increased. Currently, research on left atrial appendage closure (LAAC) in patients with AF and HF is limited and controversial. This study was designed to investigate the safety and effectiveness of LAAC in AF patients with different types of HF. Methods: Patients with non-valvular atrial fibrillation (NVAF) and HF who underwent LAAC in the First Affiliated Hospital of Army Medical University from August 2014 to July 2021 were enrolled. According to left ventricular ejection fraction (LVEF), the study divided into HF with reduced ejection fraction (LVEF < 50%, HFrEF) group and HF with preserved ejection fraction (LVEF ≥ 50%, HFpEF) group. The data we collected from patients included: gender, age, comorbid diseases, CHA
2 DS2 -VASc score, HAS-BLED score, NT-proBNP level, residual shunt, cardiac catheterization results, occluder size, postoperative medication regimen, transthoracic echocardiography (TTE) results and transesophageal echocardiography (TEE) results, etc. Patients were followed up for stroke, bleeding, device related thrombus (DRT), pericardial tamponade, hospitalization for HF, and all-cause death within 2 years after surgery. Statistical methods were used to compare the differences in clinical outcome of LAAC in AF patients with different types of HF. Results: Overall, 288 NVAF patients with HF were enrolled in this study, including 142 males and 146 females. There were 74 patients in the HFrEF group and 214 patients in the HFpEF group. All patients successfully underwent LAAC. The CHA2 DS2 -VASc score and HAS-BLED score of HFrEF group were lower than those of HFpEF group. A total of 288 LAAC devices were implanted. The average diameter of the occluders was 27.2 ± 3.5 mm in the HFrEF group and 26.8 ± 3.3 mm in the HFpEF group, and there was no statistical difference between the two groups (P = 0.470). Also, there was no statistically significant difference in the occurrence of residual shunts between the two groups as detected by TEE after surgery (P = 0.341). LVEF was significantly higher in HFrEF group at 3 days, 3 months and 1 year after operation than before (P < 0.001). At 45–60 days after surgery, we found DRT in 9 patients and there were 4 patients (5.4%) in HFrEF group and 5 patients (2.3%) in HFpEF group, with no significant difference between the two groups (P = 0.357). One patient with DRT had stroke. The incidence of stroke was 11.1% in patients with DRT and 0.7% in patients without DRT (P = 0.670). There was one case of postoperative pericardial tamponade, which was improved by pericardiocentesis at 24 h after surgery in the HFpEF group, and there was no significant difference between the two groups (P = 1.000). During a mean follow-up period of 49.7 ± 22.4 months, there were no significant differences in the incidence of stroke, bleeding, DRT and HF exacerbation between the two groups. We found a statistical difference in the improvement of HF between HFrEF group and HFpEF group (P < 0.05). Conclusions: LAAC is safe and effective in AF patients with different types of HF. The improvement of cardiac function after LAAC is more pronounced in HFrEF group than in HFpEF group. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
9. Position Statement on Cardiac Computed Tomography Following Left Atrial Appendage Occlusion.
- Author
-
Korsholm, Kasper, Iriart, Xavier, Saw, Jacqueline, Wang, Dee Dee, Berti, Sergio, Galea, Roberto, Freixa, Xavier, Arzamendi, Dabit, De Backer, Ole, Kramer, Anders, Cademartiri, Filippo, Cochet, Hubert, Odenstedt, Jacob, Aminian, Adel, Räber, Lorenz, Cruz-Gonzalez, Ignacio, Garot, Philippe, Jensen, Jesper Møller, Alkhouli, Mohamad, and Nielsen-Kudsk, Jens Erik
- Abstract
Left atrial appendage occlusion (LAAO) is rapidly growing as valid stroke prevention therapy in atrial fibrillation. Cardiac imaging plays an instrumental role in preprocedural planning, procedural execution, and postprocedural follow-up. Recently, cardiac computed tomography (CCT) has made significant advancements, resulting in increasing use both preprocedurally and in outpatient follow-up. It provides a noninvasive, high-resolution alternative to the current standard, transesophageal echocardiography, and may display advantages in both the detection and characterization of device-specific complications, such as peridevice leak and device-related thrombosis. The implementation of CCT in the follow-up after LAAO has identified new findings such as hypoattenuated thickening on the atrial device surface and left atrial appendage contrast patency, which are not readily assessable on transesophageal echocardiography. Currently, there is a lack of standardization for acquisition and interpretation of images and consensus on definitions of essential findings on CCT in the postprocedural phase. This paper intends to provide a practical and standardized approach to both acquisition and interpretation of CCT after LAAO based on a comprehensive review of the literature and expert consensus among European and North American interventional and imaging specialists. [Display omitted] • CCT is increasingly used as follow-up imaging after LAAO. • CCT has identified new findings such as HAT on the atrial device surface and LAA contrast patency. • CCT features an unparalleled ability to detect and characterize PDL, HAT, and overt device thrombosis. • CCT may provide a rich source of data, elevating our understanding of several fundamental issues in LAAO. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Watchman vs. Amulet for Left Atrial Appendage Closure: Current Evidence and Future Perspectives.
- Author
-
Frazzetto, Marco, Sanfilippo, Claudio, Costa, Giuliano, Contrafatto, Claudia, Giacalone, Chiara, Scandura, Salvatore, Castania, Giuseppe, De Santis, Jessica, Sanfilippo, Maria, Di Salvo, Maria Elena, Tamburino, Corrado, Barbanti, Marco, and Grasso, Carmelo
- Subjects
LEFT atrial appendage closure ,ATRIAL fibrillation ,AMULETS ,STROKE ,STROKE patients - Abstract
Left atrial appendage closure (LAAC) is a crucial intervention for stroke prevention in patients with non-valvular atrial fibrillation who are unsuitable for long-term anticoagulation. Amulet and Watchman are the most implanted devices worldwide for performing LAAC, and the aim of this review is to provide a comprehensive comparison focusing on their efficacy, safety, and short- and long-term outcomes. The Watchman device, the first to gain FDA approval, has been extensively studied and demonstrates significant reductions in stroke and systemic embolism rates. The Amulet device, a newer alternative, promises enhanced design features for more efficient appendage sealing. Current data highlight that both devices offer similar efficacy and safety for LAAC. While the two devices differ in terms of intraprocedural complication rates, they offer similar short- to long-term outcomes in terms of peri-device leaks, device-related thrombosis, and mortality. Both devices are indicated for patients who are unable to tolerate OAC, given their similar risk and safety profiles. Newer clinical studies are directed at establishing the efficacy of both devices as the primary method for stroke prevention in AF as an alternative to OAC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. Safety and feasibility of atrial fibrillation ablation after left atrial appendage closure: A single‐center experience of the left atrial appendage closure first strategy.
- Author
-
Chatani, Ryuki, Kubo, Shunsuke, Tasaka, Hiroshi, Sakata, Atsushi, Yoshino, Mitsuru, Maruo, Takeshi, and Kadota, Kazushige
- Subjects
TRANSESOPHAGEAL echocardiography ,PATIENT safety ,EARLY medical intervention ,TREATMENT effectiveness ,FIBRINOLYTIC agents ,ATRIAL fibrillation ,ISCHEMIC stroke ,CATHETER ablation ,LEFT atrial appendage closure ,GENERAL anesthesia ,THROMBOSIS - Abstract
Background: Patients with atrial fibrillation (AF) who are not suitable for long‐term anticoagulant therapy undergo percutaneous left atrial appendage closure (LAAC). The safety and feasibility of left atrial catheter ablation (CA) procedures after LAAC remain unclear. This study aimed to clarify the feasibility and safety of CA after LAAC, including in the early phase within 180 days. Methods: Characteristics and clinical outcomes of 46 patients with AF who had undergone both CA and LAAC within 2 years (mean age, 72 years; 29 men) were compared between those who had undergone CA‐first (31 patients) and LAAC‐first (15 patients). Results: The mean CHA₂DS₂‐VASc and HAS‐BLED scores were 4.8 and 3.3 points, respectively. The LAAC‐first strategy was often used in patients with prior major bleeding and LAA thrombosis or sludge. In the LAAC‐first group, the mean duration between both procedures was 212 days, and all LAAC‐first patients, including seven patients in the early phase, could undergo CA without LAAC device‐related complications; moreover, no cardiovascular adverse events were reported after both procedures (mean periods: 420 days). After CA post‐LAAC, no device‐related adverse events (device‐related thrombosis, new peri‐device leak appearance, peri‐device leak increase, or device dislodgement) were observed, whereas, after LAAC post‐CA, 3 new peri‐device leak appearance events and 1 peri‐device leak increase event were observed, especially patients who underwent LAAC in the early phase post‐CA. Conclusion: Based on single‐center experience, left atrial CA in the presence of an LAAC device implanted including the early phase was safe and feasible. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
12. The elephant trunk: a rare morphology of the left atrial appendage—a case report.
- Author
-
Fischer, Patrick, Mahfoud, Felix, Böhm, Michael, and Ukena, Christian
- Subjects
LEFT heart atrium ,CEREBRAL embolism & thrombosis ,CONTRAST media ,ELEPHANTS ,LEFT atrial appendage closure ,ATRIAL fibrillation - Abstract
Background Patients with atrial fibrillation (AF) are at increased risk for thromboembolic events including stroke. The primary source for thromboembolism in these patients is thrombus formation in the left atrial appendage (LAA). Depending on the individual thromboembolic risk, long-term anticoagulation is recommended. In certain patients, however, long-term anticoagulation is contraindicated, and interventional closure of the LAA (LAAC) represents an alternative approach to lower the thromboembolic risk and avoid oral anticoagulation. Case summary An 83-year-old male underwent LAAC at our centre in November 2022. Prior to the procedure, a thrombus in the left atrium (LA) or LAA was excluded by transoesophageal echocardiography (TOE), and the anatomy of the LAA was assessed as eligible for LAAC with no evidence of anatomical irregularities. After contrast medium injection, angiography revealed an atypical anatomic variant of the LAA with a substantially long, elephant trunk–like course. Discussion We present a previously not described unique anatomic variant of the LAA: the elephant trunk morphology. Left atrial appendage anatomy is very heterogeneous, and detailed knowledge of LAA morphology is important for endovascular LAA procedures as well as for predicting the risk of thromboembolic events. Despite thorough pre-procedural imaging, anatomic variants may remain obscured. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. Treatment strategies of the thromboembolic risk in kidney failure patients with atrial fibrillation.
- Author
-
Genovesi, Simonetta, Camm, A John, Covic, Adrian, Burlacu, Alexandru, Meijers, Björn, Franssen, Casper, Luyckx, Valerie, Liakopoulos, Vassilios, Alfano, Gaetano, Combe, Christian, and Basile, Carlo
- Subjects
LEFT atrial appendage closure ,ANTICOAGULANTS ,KIDNEY failure ,ATRIAL fibrillation ,ORAL medication - Abstract
The incidence and prevalence of atrial fibrillation (AF) in patients affected by kidney failure, i.e. glomerular filtration rate <15 ml/min/1.73 m
2 , is high and probably underestimated. Numerous uncertainties remain regarding how to prevent thromboembolic events in this population because both cardiology and nephrology guidelines do not provide clear recommendations. The efficacy and safety of oral anticoagulant therapy (OAC) in preventing thromboembolism in patients with kidney failure and AF has not been demonstrated for either vitamin K antagonists (VKAs) or direct anticoagulants (DOACs). Moreover, it remains unclear which is more effective and safer, because estimated creatinine clearance <25–30 ml/min was an exclusion criterion in the randomized controlled trials (RCTs). Three RCTs comparing DOACs and VKAs in kidney failure failed to reach the primary endpoint, as they were underpowered. The left atrial appendage is the main source of thromboembolism in the presence of AF. Left atrial appendage closure (LAAC) has recently been proposed as an alternative to OAC. RCTs comparing the efficacy and safety of LAAC versus OAC in kidney failure were terminated prematurely due to recruitment failure. A recent prospective study showed a reduction in thromboembolic events in haemodialysis patients with AF and undergoing LAAC compared with patients taking or not taking OAC. We review current treatment standards and discuss recent developments in managing the thromboembolic risk in kidney failure patients with AF. The importance of shared decision-making with the multidisciplinary team and the patient to consider individual risks and benefits of each treatment option is underlined. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
14. What characterizes device‐related thrombosis following LAAC, if ejection fraction fails to shine?
- Author
-
Kerkhof, Peter L. M., Osto, Elena, and Handly, Neal
- Subjects
THROMBOSIS risk factors ,RISK assessment ,REFERENCE values ,VENTRICULAR ejection fraction ,SEX distribution ,AGE distribution ,ATRIAL fibrillation ,LEFT atrial appendage closure - Abstract
Cardiac compartmental size depends on sex, with smaller values found in (healthy) women compared to a matched group of men. Various types of heart disease may cause dilation of the affected chamber. For example, atrial fibrillation (AF) is associated with enlarged left atrial (LA) size, often also implying increased left ventricular (LV) size. Sex‐specific differences appear to persist during disease states. Thus, chamber volumes depend on both sex and the severity of the underlying disorder, and require quantification to evaluate the effect of interventions. Often, we rely on the popular performance metric ejection fraction (EF) which refers to the ratio of the minimum and maximum LV or LA volumetric values observed during the cardiac cycle. Here we discuss a sex stratified analysis of LVEF and LAEF in AF patients as treated by LA appendage closure, while comparing those with or without device‐related thrombosis. Also, an alternative analysis based on primary data is presented while emphasizing its attractiveness. In any event, age‐ and sex‐specific reference values as broadly documented for various imaging modalities should be applied to LA and LV. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
15. Impact of gender in patients with device‐related thrombosis after left atrial appendage closure – A sub‐analysis from the multicenter EUROC‐DRT‐registry.
- Author
-
Saw, Jacqueline, Vij, Vivian, Galea, Roberto, Piayda, Kerstin, Nelles, Dominik, Vogt, Lara, Gloekler, Steffen, Fürholz, Monika, Meier, Bernhard, Räber, Lorenz, O'Hara, Gilles, Arzamendi, Dabit, Agudelo, Victor, Asmarats, Lluis, Freixa, Xavier, Flores‐Umanzor, Eduardo, De Backer, Ole, Sondergaard, Lars, Nombela‐Franco, Luis, and Salinas, Pablo
- Subjects
THROMBOSIS risk factors ,RISK assessment ,PROSTHETICS ,ANTICOAGULANTS ,SEX distribution ,ARTIFICIAL implants ,DESCRIPTIVE statistics ,REPORTING of diseases ,VITAMIN K ,SURGICAL complications ,KAPLAN-Meier estimator ,ATRIAL fibrillation ,LEFT atrial appendage closure ,ADVERSE health care events ,CONFIDENCE intervals ,STROKE ,COMORBIDITY ,CHEMICAL inhibitors - Abstract
Background: Device‐related thrombosis (DRT) is a common finding after left atrial appendage closure (LAAC) and is associated with worse outcomes. As women are underrepresented in clinical studies, further understanding of sex differences in DRT patients is warranted. Methods and Results: This sub‐analysis from the EUROC‐DRT‐registry compromises 176 patients with diagnosis of DRT after LAAC. Women, who accounted for 34.7% (61/176) of patients, were older (78.0 ± 6.7 vs. 74.9 ± 9.1 years, p =.06) with lower rates of comorbidities. While DRT was detected significantly later in women (173 ± 267 vs. 127 ± 192 days, p =.01), anticoagulation therapy was escalated similarly, mainly with initiation of novel oral anticoagulant (NOAC), vitamin K antagonist (VKA) or heparin. DRT resolution was achieved in 67.5% (27/40) of women and in 75.0% (54/72) of men (p =.40). In the remaining cases, an intensification/switch of anticoagulation was conducted in 50.% (9/18) of men and in 41.7% (5/12) of women. Final resolution was achieved in 72.5% (29/40) cases in women, and in 81.9% (59/72) cases in men (p =.24). Women were followed‐up for a similar time as men (779 ± 520 vs. 908 ± 687 days, p =.51). Kaplan–Meier analysis revealed no difference in mortality rates in women (Hazard Ratio [HR]: 1.73, 95%‐Confidence interval [95%‐CI]:.68–4.37, p =.25) and no differences in stroke (HR:.83, 95%‐CI:.30–2.32, p =.72) within 2 years after LAAC. Conclusion: Evaluation of risk factors and outcome revealed no differences between men and women, with DRT in women being diagnosed significantly later. Women should be monitored closely to assess for DRT formation/resolution. Treatment strategies appear to be equally effective. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
16. Step‐by‐step recommendations utilizing four‐dimensional intracardiac echocardiography in left atrial appendage procedures.
- Author
-
Gidney, Brett, Della Rocca, Domenico G., Horton, Rodney, Hoffman, Joel, Valderrábano, Miguel, Natale, Andrea, Garg, Jalaj, Bhardwaj, Rahul, and Doshi, Shephal
- Subjects
TRICUSPID valve surgery ,MEDICAL protocols ,WORKFLOW ,LEFT atrial appendage closure ,CATHETER ablation ,ECHOCARDIOGRAPHY - Abstract
Introduction: Four‐dimensional (4D) intracardiac echocardiography (ICE) is a novel cardiac imaging modality that has been applied to various workflows, including catheter ablation, tricuspid valve repair, and left atrial appendage occlusion (LAAO). The use of this type of advanced ICE imaging may ultimately allow for the replacement of transesophageal echocardiography (TEE) for LAAO, providing comparable imaging quality while eliminating the need for general anesthesia. Methods: Based on our initial clinical experience with 4D ICE in LAAO, we have developed an optimized workflow for the use of the NUVISION™ 4D ICE Catheter in conjunction with the GE E95 and S70N Ultrasound Systems in LAAO. In this manuscript, we provide a step‐by‐step guide to using 4D ICE in conjunction with compatible imaging consoles. We have also evaluated the performance of 4D ICE with the NUVISION Ultrasound Catheter versus TEE in one LAAO case and present those results here. Results: In our comparison of 4D ICE using our optimized workflow with TEE in an LAAO case, ICE LAA measurements were similar to those from TEE. The best image resolution was seen via ICE in 2‐dimensional and multislice modes (triplane and biplane). The FlexiSlice multiplanar reconstruction tool, which creates an en‐face image derived from a 4D volume set, also provided valuable information but yielded slightly lower image quality, as expected for these volume‐derived images. For this case, comparable images were obtained with TEE and ICE but with less need to reposition the ICE catheter. Conclusion: The use of optimized 4D ICE catheter workflow recommendations allows for efficient LAAO procedures, with higher resolution imaging, comparable to TEE. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Single versus dual antiplatelet therapy following percutaneous left atrial appendage closure—A systematic review and meta‐analysis.
- Author
-
Continisio, Saverio, Montonati, Carolina, Angelini, Filippo, Bocchino, Pier Paolo, Carbonaro, Carla, Giacobbe, Federico, Dusi, Veronica, De Filippo, Ovidio, Ielasi, Alfonso, Giannino, Giuseppe, Boldi, Emiliano, Fabris, Tommaso, D'Ascenzo, Fabrizio, De Ferrari, Gaetano Maria, and Tarantini, Giuseppe
- Subjects
LEFT atrial appendage closure ,PLATELET aggregation inhibitors ,ISCHEMIC stroke ,STROKE ,ATRIAL fibrillation - Abstract
Background: In the last few years, percutaneous LAA occlusion (LAAO) has become a plausible alternative in atrial fibrillation (AF) patients with contraindications to anticoagulation therapy. Nevertheless, the optimal antiplatelet strategy following percutaneous LAAO remains to be defined. Methods: Studies comparing single antiplatelet therapy (SAPT) versus dual antiplatelet therapy (DAPT) following LAAO were systematically searched and screened. The outcomes of interest were ischemic stroke, device‐related thrombus (DRT) and major bleeding. A random‐effect meta‐analysis was performed comparing outcomes in both groups. The moderator effect of baseline characteristics on outcomes was evaluated by univariate meta‐regression analyses. Results: Sixteen observational studies with 3255 patients treated with antiplatelet therapy (SAPT, n = 1033; DAPT, n = 2222) after LAAO were included. Mean age was 74.5 ± 8.3 years, mean CHA2DS2‐VASc and HAS‐BLED scores were 4.3 ± 1.5 and 3.2 ± 1.0, respectively. At a weighted mean follow‐up of 12.7 months, the occurrence of stroke (RR 1.33; 95% CI 0.64–2.77; p =.44), DRT (RR 1.52; 95% CI 0.90–2.58; p =.12), and the composite of stroke and DRT (RR 1.26; 95% CI 0.67–2.37; p =.47) did not differ significantly between SAPT and DAPT groups. The rate of major bleedings was also not different between groups (RR 1.41; 95% CI 0.64–3.12; p =.39). Conclusions: Among AF patients at high bleeding risk undergoing percutaneous LAAO, a post‐procedural minimalistic antiplatelet strategy with SAPT did not significantly differ from DAPT regimens regarding the rate of stroke, DRT and major bleeding. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
18. Cardiogeriatrics: the current state of the art.
- Author
-
Gaur, Akshay, Carr, Fiona, and Warriner, David
- Subjects
MITRAL valve insufficiency ,DRUG-eluting stents ,HEART failure ,NON-ST elevated myocardial infarction ,ST elevation myocardial infarction ,LEFT atrial appendage closure ,HEART valve diseases ,FRAIL elderly - Published
- 2024
- Full Text
- View/download PDF
19. Anesthetic Choice for Percutaneous Transcatheter Closure of the Left Atrial Appendage: A National Anesthesia Clinical Outcomes Registry Analysis.
- Author
-
Hickman, William, Dada, Rachel S., Thibault, Dylan, Gibson, Christina, Heller, Scott, Jagadeesan, Vikrant, and Hayanga, Heather K.
- Subjects
LEFT atrial appendage closure ,FISHER exact test ,TRANSESOPHAGEAL echocardiography ,ORAL medication ,ATRIAL fibrillation - Abstract
Context: Left atrial appendage closure (LAAC) was developed as a novel stroke prevention alternative for patients with atrial fibrillation, particularly for those not suitable for long-term oral anticoagulant therapy. Traditionally, general anesthesia (GA) has been more commonly used primarily due to the necessity of transesophageal echocardiography. Aims: Compare trends of monitored anesthesia care (MAC) versus GA for percutaneous transcatheter LAAC with endocardial implant and assess for independent variables associated with primary anesthetic choice. Settings and Design: Multi-institutional data collected from across the United States using the National Anesthesia Clinical Outcomes Registry. Material and Methods: Retrospective data analysis from 2017--2021. Statistical Analysis Used: Independent-sample t tests or Mann--Whitney U tests were used for continuous variables and Chi-square tests or Fisher's exact test for categorical variables. Multivariate logistic regression was used to assess patient and hospital characteristics. Results: A total of 19,395 patients underwent the procedure, and 352 patients (1.8%) received MAC. MAC usage trended upward from 2017--2021 ( P < 0.0001). MAC patients were more likely to have an American Society of Anesthesiologists (ASA) physical status of≥ 4 (33.6% vs 22.89%) and to have been treated at centers in the South (67.7% vs 44.2%), in rural locations (71% vs 39.5%), and with lower median annual percutaneous transcatheter LAAC volume (102 vs 153 procedures) (all P < 0.0001). In multivariate analysis, patients treated in the West had 85% lower odds of receiving MAC compared to those in the Northeast (AOR: 0.15; 95% CI 0.03--0.80, P = 0.0261). Conclusions: While GA is the most common anesthetic technique for percutaneous transcatheter closure of the left atrial appendage, a small, statistically significant increase in MAC occurred from 2017--2021. Anesthetic management for LAAC varies with geographic location. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
20. Remimazolam for simultaneous percutaneous mitral valve clip and percutaneous left atrial appendage closure in an elderly patient with impaired cardiac function: A case report.
- Author
-
Yamaguchi, Sumika, Ishida, Yusuke, Sasaki, Tomomi, Higuchi, Satoshi, Bito, Kiyoko, and Oe, Katsunori
- Subjects
LEFT atrial appendage closure ,OLDER patients ,MITRAL valve ,MITRAL valve insufficiency ,CARDIAC patients - Abstract
Key Clinical Message: Remimazolam is a short‐acting benzodiazepine sedative with a short half‐life and little circulatory depression. The safe use of remimazolam in the anesthetic management of an elderly patient with impaired cardiac function is reported. The patient's hemodynamics remained stable, and the patient was managed without serious complications. Remimazolam may be an option for sedation in elderly patients with reduced cardiac function. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
21. Best anticoagulation strategy with and without appendage occlusion for stroke‐prophylaxis in postablation atrial fibrillation patients with cardiac amyloidosis.
- Author
-
Mohanty, Sanghamitra, Torlapati, Prem Geeta, La Fazia, Vincenzo Mirco, Kurt, Merve, Gianni, Carola, MacDonald, Bryan, Mayedo, Angel, Allison, John, Bassiouny, Mohamed, Gallinghouse, G. Joseph, Burkhardt, John D., Horton, Rodney, Di Biase, Luigi, Al‐Ahmad, Amin, and Natale, Andrea
- Subjects
STROKE prevention ,ANTICOAGULANTS ,TRANSESOPHAGEAL echocardiography ,EYE hemorrhage ,CARDIAC amyloidosis ,GASTROINTESTINAL hemorrhage ,SCIENTIFIC observation ,ASPIRIN ,DESCRIPTIVE statistics ,ORAL drug administration ,ATRIAL fibrillation ,CATHETER ablation ,LEFT atrial appendage closure ,SUBDURAL hematoma - Abstract
Introduction: Both atrial fibrillation (AF) and amyloidosis increase stroke risk. We evaluated the best anticoagulation strategy in AF patients with coexistent amyloidosis. Methods: Consecutive AF patients with concomitant amyloidosis were divided into two groups based on the postablation stroke‐prophylaxis approach; group 1: left atrial appendage occlusion (LAAO) in eligible patients and group 2: oral anticoagulation (OAC). Group 1 patients were further divided into Gr. 1A: LAAO + half‐does NOAC (HD‐NOAC) for 6 months followed by aspirin 81 mg/day and Gr. 1B: LAAO + HD‐NOAC. In group 1 patients, with complete occlusion at the 45‐day transesophageal echocardiogram, patients were switched to aspirin, 81 mg/day at 6 months. In case of leak, or dense "smoke" in the left atrium (LA) or enlarged LA, they were placed on long‐term half‐dose (HD) NOAC. Group 2 patients remained on full‐dose NOAC during the whole study period. Results: A total of 92 patients were included in the analysis; group 1: 56 and group 2: 36. After the 45‐day TEE, 31 patients from group 1 remained on baby‐aspirin and 25 on HD NOAC. At 1‐year follow‐up, four stroke, one TIA and six device‐thrombus were reported in group 1A, compared to none in patients in group 1B (5/31 vs. 0/25, p =.03). No bleeding events were reported in group 1, whereas group 2 had five bleeding events (one subdural hematoma, one retinal hemorrhage, and four GI bleedings). Additionally, one stroke was reported in group 2 that happened during brief discontinuation of OAC. Conclusion: In patients with coexistent AF and amyloidosis, half‐dose NOAC following LAAO was observed to be the safest stroke‐prophylaxis strategy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
22. Clinical incidence and relevance of incomplete endothelialization in atrial fibrillation patients with Left Atrial Appendage Closure
- Author
-
Jini Zhu, Yanpeng Wang, Meifang Li, Dong Huang, Shuai Li, and Jingbo Li
- Subjects
Atrial fibrillation ,Left atrial appendage closure ,Incomplete device endothelialization ,Oral anticoagulants ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background The objective of this study is to investigate the incidence, potential risk factors, and clinical outcomes of incomplete device endothelialization (IDE) in atrial fibrillation (AF) patients undergoing Watchman left atrial appendage closure (LAAC). Methods In this study, 68 AF patients who underwent successful implantation of the Watchman device without peri-device leak (PDL) during follow-up were included. The endothelialization status was assessed using Transesophageal echocardiography (TEE) and LAA computed tomography angiography (CTA) at 6 weeks and 6 months post-implantation. Adverse cerebro-cardiac events were documented at one-year follow-up. Baseline characteristics, including age, device sizes, and clinical indicators, were analyzed as potential predictors for IDE. Results IDE was observed in 70.6% and 67.6% of patients at 6 weeks and 6 months after implantation, respectively. Higher levels of high-density lipoprotein cholesterol (HDL-C) [odds ratio (OR): 15.109, 95% confidence interval (CI): 1.637-139.478, p = 0.017 and OR: 11.015, 95% CI: 1.365–88.896, p = 0.024] and lower aspartate aminotransferase (AST) (OR 0.924, 95% CI: 0.865–0.986, p = 0.017 and OR: 0.930, 95% CI: 0.874–0.990, p = 0.023) at baseline were found to be significantly associated with IDE at 6 weeks and 6 months, respectively, although no significant difference in adverse cerebro-cardiac events was noted between incomplete and complete DE groups during 1-year follow-up Conclusions IDE is found to be a prevalent occurrence in humans following LAAC. Elevated HDL-C and reduced AST levels are shown to be linked to an increased risk of IDE after LAAC
- Published
- 2024
- Full Text
- View/download PDF
23. Safety and effectiveness of left atrial appendage closure in atrial fibrillation patients with different types of heart failure
- Author
-
Liping Liu, Wen Yan, Xiang Xu, Chen Wan, Feng Liu, Qing Yao, Ling Song, Binbin Wang, Zhiyuan Song, and Huakang Li
- Subjects
Atrial fibrillation ,Heart failure ,Left atrial appendage closure ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background Both atrial fibrillation (AF) and heart failure (HF) are common cardiovascular diseases. If the two exist together, the risk of stroke, hospitalization for HF and all-cause death is increased. Currently, research on left atrial appendage closure (LAAC) in patients with AF and HF is limited and controversial. This study was designed to investigate the safety and effectiveness of LAAC in AF patients with different types of HF. Methods Patients with non-valvular atrial fibrillation (NVAF) and HF who underwent LAAC in the First Affiliated Hospital of Army Medical University from August 2014 to July 2021 were enrolled. According to left ventricular ejection fraction (LVEF), the study divided into HF with reduced ejection fraction (LVEF
- Published
- 2024
- Full Text
- View/download PDF
24. Safety and feasibility of atrial fibrillation ablation after left atrial appendage closure: A single‐center experience of the left atrial appendage closure first strategy
- Author
-
Ryuki Chatani, Shunsuke Kubo, Hiroshi Tasaka, Atsushi Sakata, Mitsuru Yoshino, Takeshi Maruo, and Kazushige Kadota
- Subjects
antithrombotic regimen ,atrial fibrillation ,catheter ablation ,left atrial appendage closure ,peri‐device leak ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Background Patients with atrial fibrillation (AF) who are not suitable for long‐term anticoagulant therapy undergo percutaneous left atrial appendage closure (LAAC). The safety and feasibility of left atrial catheter ablation (CA) procedures after LAAC remain unclear. This study aimed to clarify the feasibility and safety of CA after LAAC, including in the early phase within 180 days. Methods Characteristics and clinical outcomes of 46 patients with AF who had undergone both CA and LAAC within 2 years (mean age, 72 years; 29 men) were compared between those who had undergone CA‐first (31 patients) and LAAC‐first (15 patients). Results The mean CHA₂DS₂‐VASc and HAS‐BLED scores were 4.8 and 3.3 points, respectively. The LAAC‐first strategy was often used in patients with prior major bleeding and LAA thrombosis or sludge. In the LAAC‐first group, the mean duration between both procedures was 212 days, and all LAAC‐first patients, including seven patients in the early phase, could undergo CA without LAAC device‐related complications; moreover, no cardiovascular adverse events were reported after both procedures (mean periods: 420 days). After CA post‐LAAC, no device‐related adverse events (device‐related thrombosis, new peri‐device leak appearance, peri‐device leak increase, or device dislodgement) were observed, whereas, after LAAC post‐CA, 3 new peri‐device leak appearance events and 1 peri‐device leak increase event were observed, especially patients who underwent LAAC in the early phase post‐CA. Conclusion Based on single‐center experience, left atrial CA in the presence of an LAAC device implanted including the early phase was safe and feasible.
- Published
- 2024
- Full Text
- View/download PDF
25. Anesthetic Choice for Percutaneous Transcatheter Closure of the Left Atrial Appendage: A National Anesthesia Clinical Outcomes Registry Analysis
- Author
-
William Hickman, Rachel S. Dada, Dylan Thibault, Christina Gibson, Scott Heller, Vikrant Jagadeesan, and Heather K. Hayanga
- Subjects
anesthesia type ,monitored anesthesia care ,percutaneous left atrial appendage closure ,Anesthesiology ,RD78.3-87.3 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Context: Left atrial appendage closure (LAAC) was developed as a novel stroke prevention alternative for patients with atrial fibrillation, particularly for those not suitable for long-term oral anticoagulant therapy. Traditionally, general anesthesia (GA) has been more commonly used primarily due to the necessity of transesophageal echocardiography. Aims: Compare trends of monitored anesthesia care (MAC) versus GA for percutaneous transcatheter LAAC with endocardial implant and assess for independent variables associated with primary anesthetic choice. Settings and Design: Multi-institutional data collected from across the United States using the National Anesthesia Clinical Outcomes Registry. Material and Methods: Retrospective data analysis from 2017–2021. Statistical Analysis Used: Independent-sample t tests or Mann–Whitney U tests were used for continuous variables and Chi-square tests or Fisher’s exact test for categorical variables. Multivariate logistic regression was used to assess patient and hospital characteristics. Results: A total of 19,395 patients underwent the procedure, and 352 patients (1.8%) received MAC. MAC usage trended upward from 2017–2021 (P < 0.0001). MAC patients were more likely to have an American Society of Anesthesiologists (ASA) physical status of≥ 4 (33.6% vs 22.89%) and to have been treated at centers in the South (67.7% vs 44.2%), in rural locations (71% vs 39.5%), and with lower median annual percutaneous transcatheter LAAC volume (102 vs 153 procedures) (all P < 0.0001). In multivariate analysis, patients treated in the West had 85% lower odds of receiving MAC compared to those in the Northeast (AOR: 0.15; 95% CI 0.03–0.80, P = 0.0261). Conclusions: While GA is the most common anesthetic technique for percutaneous transcatheter closure of the left atrial appendage, a small, statistically significant increase in MAC occurred from 2017–2021. Anesthetic management for LAAC varies with geographic location.
- Published
- 2024
- Full Text
- View/download PDF
26. Left Atrial Appendage Closure Periprocedural Imaging
- Author
-
Alfadhel, Mesfer, Saw, Jacqueline, Kelsey, Anita M., editor, Vemulapalli, Sreek, editor, and Sadeghpour, Anita, editor
- Published
- 2024
- Full Text
- View/download PDF
27. Automatic Landing Zone Plane Detection in Contrast-Enhanced Cardiac CT Volumes
- Author
-
Lockhart, Lisette, Yi, Xin, Cassady, Nathan, Nunn, Alexandra, Swingen, Cory, Amir-Khalili, Alborz, Goos, Gerhard, Founding Editor, Hartmanis, Juris, Founding Editor, Bertino, Elisa, Editorial Board Member, Gao, Wen, Editorial Board Member, Steffen, Bernhard, Editorial Board Member, Yung, Moti, Editorial Board Member, Camara, Oscar, editor, Puyol-Antón, Esther, editor, Sermesant, Maxime, editor, Suinesiaputra, Avan, editor, Tao, Qian, editor, Wang, Chengyan, editor, and Young, Alistair, editor
- Published
- 2024
- Full Text
- View/download PDF
28. Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (ANDES)
- Author
-
Josep Rodes-Cabau, Principal Investigator
- Published
- 2023
29. Frailty in Patient Undergoing Percutaneous Left Atrial Appendage Closure. (Frail-LAAC)
- Author
-
Josep Rodes-Cabau, Principal Investigator
- Published
- 2023
30. Antithrombotic Therapy in Patients Undergoing Percutaneous Left Atrial Appendage Occlusion.
- Author
-
Galea, Roberto and Räber, Lorenz
- Abstract
Percutaneous left atrial appendage closure (LAAC) is a valid alternative to oral anticoagulation to prevent ischemic stroke in patients with atrial fibrillation.The devices approved in Europe and United States for percutaneous LAAC contain metal and temporary antithrombotic therapy is strongly recommended following implantation to prevent thrombus formation on the atrial device surface. There is still uncertainty regarding to the optimal antithrombotic drug regimen after device implantation for several reasons. Thus, this review aims at summarizing the available evidence and the remaining challenges related to the management of antithrombotic therapy in the context of LAAC procedure. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
31. Left main coronary artery disease treated with beating heart surgery: 10-year single center results
- Author
-
Tomasz K. Urbanowicz, Michał Michalak, Anna Olasińska-Wiśniewska, Marcel Żukowski, Kamil Koczorowski, Bartosz Łasowski, Michał Woźnicki, Krzysztof J. Filipiak, Andrzej Tykarski, and Marek Jemielity
- Subjects
antiplatelet therapy ,atrial fibrillation ,stroke prevention ,left atrial appendage closure ,device-related thrombus ,Medicine - Published
- 2024
- Full Text
- View/download PDF
32. Incidence and predictors of device-related thrombus after left atrial appendage closure with Watchman device
- Author
-
Jakub Maksym, Piotr Scisło, Agnieszka Kapłon-Cieślicka, Zenon Huczek, Michał Marchel, Janusz Kochman, Karol Zbroński, Grzegorz Opolski, Marcin Grabowski, and Tomasz Mazurek
- Subjects
antiplatelet therapy ,atrial fibrillation ,device-related thrombus ,left atrial appendage closure ,stroke prevention ,Medicine - Published
- 2024
- Full Text
- View/download PDF
33. Ischemic stroke associated with high‐grade pedunculated device‐related thrombosis following left atrial appendage closure
- Author
-
Ryuki Chatani, Shunsuke Kubo, Hiroshi Tasaka, Takeshi Maruo, and Kazushige Kadota
- Subjects
atrial fibrillation ,device‐related thrombosis ,ischemic stroke ,left atrial appendage closure ,oral anticoagulation ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Published
- 2024
- Full Text
- View/download PDF
34. Systematic review and meta-analysis of left atrial appendage closure's influence on early and long-term mortality and strokeCentral MessagePerspective
- Author
-
Mariusz Kowalewski, MD, PhD, Michał Święczkowski, MD, Łukasz Kuźma, MD, PhD, Bart Maesen, MD, PhD, Emil Julian Dąbrowski, MD, Matteo Matteucci, MD, Jakub Batko, MD, PhD, Radosław Litwinowicz, MD, PhD, Adam Kowalówka, MD, PhD, Wojciech Wańha, MD, PhD, Federica Jiritano, MD, PhD, Giuseppe Maria Raffa, MD, PhD, Pietro Giorgio Malvindi, MD, PhD, Luigi Pannone, MD, Paolo Meani, MD, PhD, Roberto Lorusso, MD, PhD, Richard Whitlock, MD, PhD, Mark La Meir, MD, PhD, Carlo de Asmundis, MD, PhD, James Cox, MD, PhD, and Piotr Suwalski, MD, PhD
- Subjects
atrial fibrillation ,left atrial appendage closure ,heart surgery ,arrhythmia ,systematic review ,meta-analysis ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 ,Surgery ,RD1-811 - Abstract
Objective: Left atrial appendage closure (LAAC) concomitant to heart surgery in patients with underlying atrial fibrillation (AF) has gained attention because of long-term reduction of thromboembolic complications. As of mortality benefits in the setting of non-AF, data from both observational studies and randomized controlled trials are conflicting. Methods: On-line databases were screened for studies comparing LAAC versus no LAAC concomitant to other heart surgery. End points assessed were all-cause mortality and stroke at early and longest-available follow-up. Subgroup analyses stratified on preoperative AF were performed. Risk ratios (RR) with 95% CIs served as primary statistics. Results: Electronic search yielded 25 studies (N = 660 [158 patients]). There was no difference between LAAC and no LAAC in terms of early mortality. In the overall population analysis, LAAC reduced long-term mortality (RR, 0.86; 95% CI, 0.74-1.00; P = .05; I2 = 88%), reduced early stroke risk by 19% (RR, 0.81; 95% CI, 0.72-0.93; P = .002; I2 = 57%), and reduced late stroke risk by 13% (RR, 0.87; 95% CI, 0.84-0.90; P
- Published
- 2024
- Full Text
- View/download PDF
35. Impact of left atrial appendage orifice diameter on the safety and efficacy of left atrial appendage closure using the LAmbre device
- Author
-
Weidong Zhuo, Binhao Wang, Guohua Fu, Yibo Yu, Mingjun Feng, Jing Liu, Xianfeng Du, and Huimin Chu
- Subjects
Atrial fibrillation ,Left atrial appendage closure ,LAmbre device ,Orifice diameter ,Medicine (General) ,R5-920 - Abstract
Background: The diameter and shape of the left atrial appendage (LAA) orifices may influence occluder selection and the outcomes of left atrial appendage closure (LAAC) procedure. This study aimed to evaluate the impact of LAA orifice diameter on the safety and efficacy of LAAC using the LAmbre device. Methods: A total of 133 patients with nonvalvular atrial fibrillation (AF) who underwent LAAC with the LAmbre device between June 2018 and June 2020 were included in this study. The patients were categorized into two groups based on the maximal diameter of the LAA orifice: the large LAA group (n = 45) with a maximal orifice diameter of ≥31 mm, and the normal LAA group (n = 88) with a maximal orifice diameter of
- Published
- 2024
- Full Text
- View/download PDF
36. Incidence and related factors of pericardial tamponade after left atrial appendage closure in patients with non-valvular atrial fibrillation
- Author
-
WANG Binbin, XU Xiang, and WANG Xingpeng
- Subjects
atrial fibrillation ,left atrial appendage closure ,pericardial tamponade ,Medicine (General) ,R5-920 - Abstract
Objective To observe the incidence of pericardial tamponade (PT) after left atrial appendage closure (LAAC) in patients with non-valvular atrial fibrillation (NVAF), and to explore its related factors and outcomes. Methods NVAF patients who were hospitalized and treated with LAAC in Department of Cardiology of our hospital from August 2014 to March 2023 were selected for the study.The general clinical data, preoperative transthoracic echocardiography and transesophageal echocardiography data, results of routine preoperative laboratory tests, intraoperative data and follow-up data of the patients were collected through the hospital medical record management system.The enrolled patients were classified into the non-PT group (n=8) and the PT group (n=1 184) according to whether PT occurred after LAAC or not.The incidence of PT, related risk factors and outcomes were statistically analyzed. Results This study included 639 males (53.6%) and 553 females (46.4%), with an average age of 68.1±9.65 years.The CHA2DS2-VASc score was 4.51±1.72, and the HAS-BLED score was 3.36±1.09.PT occurred in 8 cases (0.67%), among them, 6 cases occurred 1 to 33 h after LAAC, and 2 cases occurred on day 19 and day 27 after LAAC.As for the results of transesophageal echocardiography (TEE) and LAA angiography, compared with the non-PT group, the PT group had the significantly larger maximum caliber of the LAA (P=0.025, P=0.015), smaller maximum depth of the LAA (P=0.028, P=0.031), and lower success rate of one-time placement of the occluder (P=0.031);The occluder compression rate of the PT group was significantly greater than that of the non-PT group (P=0.046).Multivariate analysis showed that larger maximum diameter of LAA, smaller average effective depth of LAA and larger compression rate of occluder were the main risk factors for PT.All the 8 PT patients were cured by stopping antithrombotic drugs, pericardiocentesis or surgical drainage.During a mean follow-up of 39±27 months, there were no device-related thrombosis (DRT), ischemic stroke, systemic embolism and other complications in the PT group. Conclusion The incidence of PT after LAAC is low, which is related to the large diameter of LAA, the relatively insufficient depth of the LAA and the large compression rate of the occlude.PT can be cured by stopping antithrombotic drugs and pericardiocentesis/surgical drainage.
- Published
- 2024
- Full Text
- View/download PDF
37. UV‐Triggered Hydrogel Coating of the Double Network Polyelectrolytes for Enhanced Endothelialization.
- Author
-
Wang, Xing‐wang, Yin, Yi‐jing, Wang, Jing, Yu, Hong‐mei, Tang, Qian, Chen, Zhao‐yang, Fu, Guo‐sheng, Ren, Ke‐feng, Ji, Jian, and Yu, Lu
- Subjects
LEFT atrial appendage closure ,SURFACE coatings ,LEFT heart atrium ,ELECTROSTATIC interaction ,POLYMER networks ,MEDICAL equipment - Abstract
The left atrial appendage (LAA) occluder is an important medical device for closing the LAA and preventing stroke. The device‐related thrombus (DRT) prevents the implantation of the occluder in exerting the desired therapeutic effect, which is primarily caused by the delayed endothelialization of the occluder. Functional coatings are an effective strategy for accelerating the endothelialization of occluders. However, the occluder surface area is particularly large and structurally complex, and the device is subjected to a large shear friction in the sheath during implantation, which poses a significant challenge to the coating. Herein, a hydrogel coating by the in situ UV‐triggered polymerization of double‐network polyelectrolytes is reported. The findings reveal that the double network and electrostatic interactions between the networks resulted in excellent mechanical properties of the hydrogel coating. The sulfonate and Arg‐Gly‐Asp (RGD) groups in the coating promoted hemocompatibility and endothelial growth of the occluder, respectively. The coating significantly accelerated the endothelialization of the LAA occluder in a canine model is further demonstrated. This study has potential clinical benefits in reducing both the incidence of DRT and the postoperative anticoagulant course for LAA closure. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
38. Pericardial Effusion After Left Atrial Appendage Closure: Timing, Predictors, and Clinical Impact.
- Author
-
Galea, Roberto, Bini, Tommaso, Krsnik, Juan Perich, Touray, Mariama, Temperli, Fabrice Gil, Kassar, Mohammad, Papadis, Athanasios, Gloeckler, Steffen, Brugger, Nicolas, Madhkour, Raouf, Seiffge, David Julian, Roten, Laurent, Siontis, George C.M., Heg, Dierik, Windecker, Stephan, and Räber, Lorenz
- Abstract
Pericardial effusion (PE) is the most common serious left atrial appendage closure (LAAC) complication, but its mechanisms, time course, and prognostic impact are poorly understood. This study sought to assess the frequency, timing, predictors and clinical impact of PE after LAAC. Data on consecutive patients undergoing percutaneous LAAC between 2009 and 2022 were prospectively collected including the 1-year follow-up. Both single (Watchman 2.5/FLX, Boston Scientific) and double (Amplatzer Cardiac Plug or Amulet, St. Jude Medical/Abbott) LAAC devices were used. An imaging core laboratory adjudicated the PEs and categorized them as early (≤7 days) and late (8-365 days). Logistic regression analysis was used to identify predictors of early and overall PE. Of 1,023 attempted LAAC procedures, PE was observed in 44 (4.3%) patients; PE was categorized as early in 34 (3.3%) and late in 10 (0.9%) patients. The majority of PEs occurred within 6 hours after LAAC (n = 25, 56.8%) and were clinically relevant (n = 28, 63.6%). Independent predictors of early PE were double-closure left atrial appendage devices (adjusted OR: 8.20; 95% CI: 1.09-61.69), female sex (adjusted OR: 3.41; 95% CI: 1.50-7.73), the use of oral anticoagulation (OAC) at baseline (adjusted OR: 2.60; 95% CI: 1.11-6.09), and advanced age (adjusted OR: 1.07; 95% CI: 1.01-1.23), whereas female sex and OAC at baseline remained independent predictors of overall PE. In this large LAAC registry, PE was observed in <1 in 20 patients and usually occurred within 6 hours after procedure. The majority of early PEs were clinically relevant and occurred in the Amplatzer Cardiac Plug/Amulet procedures. Independent predictors included the use of double-closure devices, female sex, OAC at baseline, and advanced age. (LAAC-registry: Clinical Outcome After Echocardiography-guided LAA-closure; NCT04628078) [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Left atrial appendage closure in a patient previously implanted with an interatrial shunt device: a case report.
- Author
-
Lin, Dawei, Li, Mingfei, Weng, Zilong, Pan, Wenzhi, Zhou, Daxin, and Ge, Junbo
- Subjects
LEFT atrial appendage closure ,LEFT heart atrium ,ARTERIAL puncture ,CEREBROSPINAL fluid shunts ,VENTRICULAR septal defects - Abstract
Patients with previous interatrial shunt device (IASD) implantation may face greater challenges during future left atrial interventional procedures. Herein, we report the first case of left atrial appendage closure (LAAC) in a patient with previous IASD implantation. The patient successfully underwent LAAC using the LAmbre device without complications. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
40. Left atrial appendage closure in patients with left atrial appendage thrombus guided by intracardiac echocardiography.
- Author
-
Wang, Binhao, Chu, Huimin, Wang, Zhao, Fu, Guohua, Yu, Yibo, Feng, Mingjun, and Du, Xianfeng
- Abstract
Data regarding left atrial appendage closure (LAAC) in patients with left atrial appendage (LAA) thrombus are limited. Recently published cases have mostly been guided by transesophageal echocardiography. Intracardiac echocardiography (ICE) is now widely used during LAAC procedures. This is the first study to report the feasibility of LAAC in patients with LAA thrombus guided by ICE. Patients with persistent LAA thrombus despite anticoagulation or contraindications to anticoagulation who underwent a modified ICE-guided LAAC procedure between June 2021 and April 2023 were included. Periprocedural events and clinical outcomes during follow-up were recorded. A total of 12 patients (mean age 65 ± 7 years; 92% male) were included: 10 with persistent LAA thrombus and 2 with contraindications to anticoagulation. Most of the thrombus was at the apex (n = 6), followed by the body (n = 3) and the ostium (n = 3). A LAmbre device was used and successfully implanted in all patients with the guidance of ICE. No thrombotic material was retrieved from patients with the protection of cerebral protection device (n = 11). No patient experienced severe periprocedural complications. All patients completed transesophageal echocardiography follow-up, and no device-related thrombus or peridevice leak > 3 mm was detected. None of the patients experienced stroke/transient ischemic attack, systemic embolism, or major bleeding events during a median follow-up of 147 days (interquartile range 80–306 days). LAAC using the LAmbre device guided by ICE may be feasible in patients with LAA thrombus when performed by experienced operators. [Display omitted] [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
41. Procedure Volume and Outcomes With WATCHMAN Left Atrial Appendage Occlusion.
- Author
-
Friedman, Daniel J., Chengan Du, Zimmerman, Sarah, Zhen Tan, Zhenqiu Lin, Vemulapalli, Sreekanth, Kosinski, Andrzej S., Piccini, Jonathan P., Pereira, Lucy, Minges, Karl E., Faridi, Kamil F., Masoudi, Frederick A., Curtis, Jeptha P., and Freeman, James V.
- Abstract
BACKGROUND: Procedure volumes are associated with outcomes for many cardiovascular procedures, leading to guidelines on minimum volume thresholds for certain procedures; however, the volume-outcome relationship with left atrial appendage occlusion is poorly understood. As such, we sought to determine the relationship between hospital and physician volume and WATCHMAN left atrial appendage occlusion procedural success overall and with the new generation WATCHMAN FLX device. METHODS: We performed an analysis of WATCHMAN procedures (January 2019 to October 2021) from the National Cardiovascular Data Registry LAAO Registry. Three-level hierarchical generalized linear models were used to assess the adjusted relationship between procedure volume and procedural success (device released with peridevice leak <5 mm, no in-hospital major adverse events). RESULTS: Among 87480 patients (76.2±8.0 years; 58.8% men; mean CHA
2 DS2 -VASc score, 4.8±1.5) from 693 hospitals, the procedural success rate was 94.2%. With hospital volume Q4 (greatest volume) as the reference, the likelihood of procedural success was significantly less among Q1 (odds ratio [OR], 0.66 [CI, 0.57–0.77]) and Q2 (OR, 0.78 [CI, 0.69– 0.90]) but not Q3 (OR, 0.95 [CI, 0.84–1.07]). With physician volume Q4 (greatest volume) as the reference, the likelihood of procedural success was significantly less among Q1 (OR, 0.72 [CI, 0.63–0.82]), Q2 (OR, 0.79 [CI, 0.71–0.89]), and Q3 (OR, 0.88 [CI, 0.79–0.97]). Among WATCHMAN FLX procedures, there was attenuation of the volume-outcome relationships, with statistically significant but modest absolute differences of only ≈1% across volume quartiles. CONCLUSIONS: In this contemporary national analysis, greater hospital and physician WATCHMAN volumes were associated with increased procedure success. The WATCHMAN FLX transition was associated with increased procedural success and less heterogeneity in outcomes across volume quartiles. These findings indicate the importance of understanding the volume-outcome relationship for individual left atrial appendage occlusion devices. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
42. Difetti emostatici in un paziente in trattamento con anticoagulanti orali diretti.
- Author
-
Casini, Monica, Pavia, Tiziana, Martelloni, Monica, Meini, Simone, Bracalente, Irene, Cois, Claudia, Valentini, Paola, Marcucci, Rossella, Linari, Silvia, and Macchia, Lucia
- Subjects
LEFT atrial appendage closure ,BLOOD coagulation factor XIII ,BLOOD coagulation factors ,ATRIAL fibrillation ,CONGENITAL disorders ,HEMOPHILIA ,STOMACH ulcers - Abstract
This case report concerns a 68-year-old man with atrial fibrillation who was being treated with edoxaban, a direct oral anticoagulant, to prevent stroke. In the patient's medical history, two episodes of post-surgical hemorrhagic diathesis were not investigated. He sought First Aid for intense asthenia and dark stool discharge. He presented with severe anemia (hemoglobin 40 g/L) and extended coagulation tests (prothrombin ratio 8.56; activated partial thromboplastin ratio 3.83), antral gastritis, and a gastric ulcer. The prolongation of both coagulation tests suggested a decrease in the activity of one of the common pathway factors. The subsequent performance of a mixing test, which helps to distinguish clotting time prolongation due to a coagulation factor deficiency rather than to an inhibitor, allowed us to understand that the patient might be suffering from a factor congenital deficiency. Measurements of coagulation factors showed a severe reduction in factor V activity (1.1%). The search for specific inhibitors directed against factor V was negative, confirming the suspicion that it was a congenital deficiency of factor V, a rare autosomal recessive disorder. Anticoagulant therapy and gastric ulcer made it possible to diagnose a rare congenital disease in an elderly man. The anticoagulant therapy was interrupted and a surgical closure of the left atrial appendage was established. Before starting anticoagulant therapy, according to consolidated guidelines, a blood count, full coagulation panel, renal, and liver function must be evaluated. Very likely, the patient, affected by congenital factor V deficiency, started the anticoagulant therapy without an adequate evaluation of the hemostasis status. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Inter‐atrial septal balloon dilation to facilitate intracardiac echocardiography guided left atrial appendage occlusion.
- Author
-
Goyal, Sandeep K., Bhimani, Ashish A., Kella, Danesh K., Tyagi, Anahita, Polsani, Venkateshwar, and Deering, Thomas F.
- Subjects
PREDICTIVE tests ,ATRIAL septum ,PATIENT safety ,SCIENTIFIC observation ,COMPUTED tomography ,CATHETERIZATION ,TREATMENT duration ,TREATMENT effectiveness ,RETROSPECTIVE studies ,LONGITUDINAL method ,CASE-control method ,LEFT atrial appendage closure ,ECHOCARDIOGRAPHY ,TIME ,FLUOROSCOPY - Abstract
Introduction: Percutaneous left atrial appendage occlusion (LAAO) is traditionally performed under general anesthesia with trans‐esophageal echocardiography guidance. Intracardiac echo (ICE)‐guided LAAO closure is increasing in clinical use. The ICE catheter is crossed into LA via interatrial septum (IAS) after the septum is dilated with LAAO delivery sheath. This step can be time‐consuming and requires significant ICE catheter manipulation, which increases the risk of cardiac perforation. Pre‐emptive septal balloon dilation can potentially help with ICE advancement in the LA. We sought to evaluate the effect of pre‐dilation of the IAS with an 8 mm balloon on the ease of crossing the ICE catheter, fluoroscopy time for crossing, and overall procedure time. Methods: The Piedmont LAAO registry was used to identify consecutive patients who underwent LAAO. The initial 25 patients in whom balloon dilation of the IAS was performed served as the experimental cohort, and the 25 consecutive patients before that in whom balloon dilation was not performed served as controls. In the experimental group, after a trans‐septal puncture, the sheath was retracted to the right atrium with a guidewire still in the LA. An 8 × 40 mm Evercoss™ over the wire balloon was inflated across the IAS. The ICE catheter was then crossed into the LA using the fluoroscopic landmark of the guide wire and the ICE imaging. The sheath was then advanced along the ICE catheter via the transseptal puncture (TSP) and the procedure continued. Follow‐up compputed tomography imaging was obtained at 4–8 weeks. Results: Each group consisted of 25 patients. There were no significant differences in baseline characteristics. All procedures were performed successfully under conscious sedation and ICE guidance. There was a significant reduction in the overall procedure time, fluoroscopy time, and time for transseptal puncture to ICE in LA. There was no difference in the size of the acute residual interatrial shunt, as measured via ICE, or the size and presence of iatrogenic ASD at follow‐up. Conclusion: Balloon dilation of TSP is safe and is associated with increased efficiency in ICE‐guided LAAO procedures. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
44. Comparison of left atrial appendage measurements between conventional transesophageal echocardiography and "Virtual TEE" reconstructed from computed tomography for pre-procedural planning of device closure.
- Author
-
Cho, Natsuki, Nakajima, Yoshifumi, Kubo, Shunsuke, Hara, Hidehiko, Nanasato, Mamoru, Hozawa, Maiko, Doi, Akio, and Morino, Yoshihiro
- Subjects
LEFT heart atrium ,COMPUTED tomography ,LEFT atrial appendage closure ,ATRIAL fibrillation ,CARDIOGRAPHIC tomography ,TRANSESOPHAGEAL echocardiography - Abstract
For pre-procedural planning of left atrial appendage (LAA) closure, sizing is crucial. Although transesophageal echocardiography (TEE) is a standard modality, cardiac computed tomography (CT) is also widely used. The virtual TEE (V-TEE) that our group developed enables us to reconstruct images similar to TEE images from CT images. The software should be helpful to understand and plan the procedure strategy. Accordingly, we investigated the utility of V-TEE. Sixty-six patients at 4 participating sites who completed both CT and TEE prior to LAA closure were included. The LAA diameter at the landing zone (LZ) for WATCHMAN™ device implantation was statistically compared at 0°, 45°, 90°, and 135° between V-TEE and TEE. Among 66 cases, only 3 cases were excluded due to poor imaging quality, and 63 cases were analyzed. The device LZ diameters based on V-TEE were strongly correlated with those based on TEE, despite the significantly greater diameter based on V-TEE with mean differences of 2.4 to 3.0 mm (all of them: P < 0.001). The discordances (V-TEE/TEE ratio) at most angles were significantly larger in the elliptical LAAs. V-TEE provides a valuable method for the evaluation of the LAA diameters. V-TEE-based measurements were larger than conventional TEE-based measurements, especially in cases of elliptical LAAs. The assessment by V-TEE has the potential benefit of ensuring proper device sizing regardless of the LAA morphology. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Case report: three ways to mitigate the risk of embolization during left atrial appendage closure in a patient with a massive and proximal left atrial appendage thrombus.
- Author
-
Zendjebil, Sandra, Horvilleur, Jérôme, Boilève, Victor, Millien, Vincent, and Garot, Philippe
- Subjects
LEFT atrial appendage closure ,LEFT heart atrium ,THROMBOSIS ,ORAL medication - Abstract
Background Left atrial appendage (LAA) thrombus is a contraindication for LAA closure (LAAC). However, in selected cases, oral anticoagulants are strictly contraindicated because of a history of life-threatening bleeding, and LAAC remains the only possible therapy to avoid systemic and especially cerebral embolization. Case summary We report a case of LAAC despite a massive proximal thrombus in a patient who had an absolute contraindication to anticoagulant therapy, with thorough pre-planning using CT scan, device modelling and thrombus trapping techniques to reduce the risk of systemic embolic events and perform LAAC safely. Discussion Although LAAC remains at high risk in this setting, the use of cautious techniques and tools, from pre-procedure planning to systemic embolization prevention systems associated to a precise transoesopheageal echocardiography guiding throughout the procedure, allows it to be performed as safely as possible when no other option is available. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. Real-world experience utilizing the nuvision 4D intracardiac echocardiography catheter for left atrial appendage closure.
- Author
-
Adams, Alex, Mahmood, Riaz, Balaji, Nivedha, Dixit, Priyadarshini, Weisman, David, and Chandra, Shalabh
- Subjects
LEFT atrial appendage closure ,ECHOCARDIOGRAPHY ,TRANSESOPHAGEAL echocardiography ,CATHETERS ,THREE-dimensional imaging - Abstract
Transesophageal echocardiography (TEE) has been the preferred imaging modality to help guide left atrial appendage closure. Newer technologies such as the Nuvision 4D Intracardiac echocardiography (ICE) catheter allow for real-time 3D imaging of cardiac anatomy. There are no direct comparison studies for procedural imaging between TEE and 4D ICE. To evaluate the performance and safety of left atrial appendage (LAA) closure procedures with the Watchman FLX and Amulet, guided by the Nuvision 4D ICE Catheter. This retrospective observational analysis was conducted on institutional LAAO National Cardiovascular Data Registry from January 2022 to March 2023. Patients had undergone LAA closure procedures with the Watchman FLX or Amulet device guided by TEE or a 4D ICE Catheter. The primary outcome evaluated was successful LAAO device placement. A total of 121 patients underwent LAAO device placement with 46 (38.0%) patients guided by 4D ICE during LAAO implantation. The 4D ICE group had a shorter procedural time compared with TEE guidance. Post procedural 45-day TEE post implant was also comparable for both groups with no patients in either group having incomplete closure of the left atrial appendage and peri-device leak > 5 mm. No device related complications (device related access, stroke, or pericardial effusion) occurred in either group at follow-up. There was no significant difference in device implant success or post procedural outcomes at 45 days in either the TEE or 4D ICE group. However, there was a noticeable improvement in procedural time with the 4D ICE catheter. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Impact of left atrial appendage orifice diameter on the safety and efficacy of left atrial appendage closure using the LAmbre device.
- Author
-
Zhuo, Weidong, Wang, Binhao, Fu, Guohua, Yu, Yibo, Feng, Mingjun, Liu, Jing, Du, Xianfeng, and Chu, Huimin
- Subjects
LEFT atrial appendage closure ,LEFT heart atrium - Abstract
The diameter and shape of the left atrial appendage (LAA) orifices may influence occluder selection and the outcomes of left atrial appendage closure (LAAC) procedure. This study aimed to evaluate the impact of LAA orifice diameter on the safety and efficacy of LAAC using the LAmbre device. A total of 133 patients with nonvalvular atrial fibrillation (AF) who underwent LAAC with the LAmbre device between June 2018 and June 2020 were included in this study. The patients were categorized into two groups based on the maximal diameter of the LAA orifice: the large LAA group (n = 45) with a maximal orifice diameter of ≥31 mm, and the normal LAA group (n = 88) with a maximal orifice diameter of <31 mm. The study assessed periprocedural characteristics and long-term clinical follow-up. Successful implantation of the LAmbre device was observed in all patients. The incidence of periprocedural peridevice leakage (PDL) was significantly higher in the large LAA group (P < 0.001), while the incidence of acute pericardial effusion (PE) during the procedure was comparable between the two groups (P = 1.000). After a mean follow‐up period of 4.8 ± 1.7 years, three patients in the large LAA group developed delayed PE, while no patients in the normal LAA group did (P = 0.037). Additionally, a larger LAA maximal orifice diameter was associated with a higher prevalence of PDL (P = 0.001) and PE (including both acute and delayed PE) (P = 0.027). The optimal cutoff value of the LAA maximal orifice diameter for predicting PDL and PE after LAAC with the LAmbre device was determined to be 30 mm. The findings suggest that the LAmbre device is a safe and feasible option for occluding the LAA, regardless of its orifice diameter. However, it is important to note that a larger LAA orifice diameter may increase the risk of PDL and delayed PE. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Combined TAVR and LAAO Studied in a Randomized Controlled Trial.
- Subjects
STROKE prevention ,ANTICOAGULANTS ,HEART atrium ,HEART valve prosthesis implantation ,SURGICAL complications ,ATRIAL fibrillation ,COMBINED modality therapy ,LEFT atrial appendage closure ,HEMORRHAGE - Abstract
The article discusses the results of a randomized controlled trial evaluating the efficacy of concomitant left atrial appendage occlusion (LAAO) during transcatheter aortic valve replacement (TAVR) in patients with atrial fibrillation. It mentions the noninferiority of TAVR combined with LAAO compared to TAVR alone in terms of the composite endpoint of death, stroke, and bleeding at two years, highlighting the procedural complexities and potential risks associated with the combined approach.
- Published
- 2024
49. Prognostic Impact of Left Atrial Appendage Patency After Device Closure.
- Author
-
Mu Chen, Peng-Cheng Yao, Zhen-Tao Fei, Qun-Shan Wang, Yi-Chi Yu, Peng-Pai Zhang, Wei Li, Rui Zhang, Bin-Feng Mo, Ming-Zhe Zhao, Yi Yu, Mei Yang, Yan Zhao, Chang-Qi Gong, Jian Sun, and Yi-Gang Li
- Abstract
BACKGROUND: The prognostic impact of left atrial appendage (LAA) patency, including those with and without visible peridevice leak (PDL), post--LAA closure in patients with atrial fibrillation, remains elusive. METHODS: Patients with atrial fibrillation implanted with the WATCHMAN 2.5 device were prospectively enrolled. The device surveillance by cardiac computed tomography angiography was performed at 3 months post-procedure. Adverse events, including stroke/transient ischemic attack (TIA), major bleeding, cardiovascular death, all-cause death, and the combined major adverse events (MAEs), were compared between patients with complete closure and LAA patency. RESULTS: Among 519 patients with cardiac computed tomography angiography surveillance at 3 months post--LAA closure, 271 (52.2%) showed complete closure, and LAA patency was detected in 248 (47.8%) patients, including 196 (37.8%) with visible PDL and 52 (10.0%) without visible PDL. During a median of 1193 (787-1543) days follow-up, the presence of LAA patency was associated with increased risks of stroke/TIA (adjusted hazard ratio for baseline differences, 3.22 [95% CI, 1.17-8.83]; P=0.023) and MAEs (adjusted hazard ratio, 1.12 [95% CI, 1.06-1.17]; P=0.003). Specifically, LAA patency with visible PDL was associated with increased risks of stroke/TIA (hazard ratio, 3.66 [95% CI, 1.29-10.42]; P=0.015) and MAEs (hazard ratio, 3.71 [95% CI, 1.71-8.07]; P=0.001), although LAA patency without visible PDL showed higher risks of MAEs (hazard ratio, 3.59 [95% CI, 1.28--10.09]; P=0.015). Incidences of stroke/TIA (2.8% versus 3.0% versus 6.7% versus 22.2%; P=0.010), cardiovascular death (0.9% versus 0% versus 1.7% versus 11.1%; P=0.005), and MAEs (4.6% versus 9.0% versus 11.7% versus 22.2%; P=0.017) increased with larger PDL (0, >0 to ≤3, >3 to ≤5, or >5 mm). Older age and discontinuing antiplatelet therapy at 6 months were independent predictors of stroke/TIA and MAEs in patients with LAA patency. CONCLUSIONS: LAA patency detected by cardiac computed tomography angiography at 3 months post--LAA closure is associated with unfavorable prognosis in patients with atrial fibrillation implanted with WATCHMAN 2.5 device. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Displacement of occluder after left atrial appendage closure: A case report.
- Author
-
Lin, Yan and Mao, Xiaobo
- Subjects
LEFT atrial appendage closure ,LEFT heart atrium ,ATRIAL fibrillation ,ATRIAL flutter ,CEREBRAL embolism & thrombosis - Abstract
Key Clinical Message: Atrial fibrillation is closely associated with thrombotic events. In non‐valvular atrial fibrillation, 90% of thrombi are formed by the left atrial appendage. Left atrial appendage occlusion (LAAC) can effectively prevent the detachment of left atrial appendage thrombus during atrial fibrillation, thereby reducing the risk of long‐term disability or death caused by thromboembolic events. However, the identification and management of complications in LAAC are also very important. The efficacy and safety of left atrial appendage occlusion (LAAC) in preventing non‐valvular atrial fibrillation stroke have been confirmed by multiple randomized controlled and registered studies, and have been recommended by several guidelines for stroke prevention in patients with atrial fibrillation at high‐risk of stroke. We reported an 80‐year‐old male patient with persistent atrial fibrillation. The patient underwent left atrial appendage closure surgery due to high risk of embolism and bleeding. On the second day after surgery, echocardiography showed displacement of the left atrial appendage occluder. Immediately perform removal of left atrial appendage occlude and left atrial appendage occlusion on the same day, and the patient was discharged on the fifth day after surgery without any special circumstances. This case demonstrates the feasibility and important clinical significance of using interventional surgery to remove the left atrial appendage occluder after displacement in clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.